In this episode of the Enjoy Life Healthier podcast, host Jason Kam engages with Professor Baroness Susan Greenfield, a leading expert in neurodegeneration and Alzheimer's disease. They discuss the nature of neurodegeneration, the differences between dementia and Alzheimer's, early symptoms to watch for, risk factors, and preventative measures. Greenfield also shares insights into the challenges of Alzheimer's research, the innovative work being done at her company NeuroBio, and the potential for new diagnostic tests and treatments that could change the landscape of Alzheimer's care.

Takeaways:

• Neurodegeneration involves the gradual death of neurons, affecting brain function.
• Dementia is often confused with Alzheimer's, but not all dementia is Alzheimer's.
• Early symptoms of dementia include short-term memory loss and changes in behavior.
• Genetic and environmental factors can increase the risk of Alzheimer's.
• Exercise and cognitive engagement can help mitigate the risk of Alzheimer's.
• Current Alzheimer's treatments focus on amyloid, but this approach has limitations.
• NeuroBio is developing a drug that could prevent Alzheimer's symptoms from appearing.
• A pre-symptomatic diagnostic test for Alzheimer's is in development.
• T14 is a key factor in the degeneration process of Alzheimer's.
• The future of Alzheimer's treatment may involve both prevention and early intervention strategies.

Professor Susan Greenfield is a globally renowned neuroscientist, author, and broadcaster who has served as Professor of Pharmacology at the University of Oxford and as Director of the Royal Institution of Great Britain. A life peer in the House of Lords and one of Britain’s most influential scientific figures, she is celebrated for her pioneering research into neurodegeneration, consciousness, and the impact of 21st-century technology on the human brain. With over 28 honorary degrees and accolades including a CBE and the Legion d’Honneur, Professor Greenfield continues to inspire new thinking about how science shapes our identity and future.

She is also the founder and CEO of Neuro-Bio Ltd, a biotech company leading the charge in innovative solutions for neurodegenerative diseases like Alzheimer’s and Parkinson’s. Neuro-Bio is developing a first-of-its-kind pre-symptomatic test for Alzheimer’s and a novel compound, NBP-14, designed to halt the root causes of neuronal degeneration. Professor Greenfield’s work through Neuro-Bio offers a hopeful vision for earlier detection, more effective treatment, and a future where these devastating conditions can be caught before they take hold. Learn more at www.neuro-bio.com.